Team

Our Team Keith Barksdale Managing Director & Co-Founder (212) 972-0900 x204 office (212) 584-4549 direct keith@ledgemontcapital.com Mr. Barksdale has experience in portfolio management and institutional equity sales. Prior to co-founding Ledgemont Capital Group, he was a Managing Director of Indigo Merchant Capital Group, where he was involved in capital raising, management recruiting, and overall strategic and financial advisory services to growth stage companies. Prior to Indigo, Mr. Barksdale was a Managing Partner of Third Ridge Capital Management, LLC, a long/short U.S. equity hedge fund. Third Ridge merged with Indigo in 2004. Previously, he was a Managing Director and Portfolio Manager at Masters Capital, where he was a member of a team managing over $650m in assets that achieved net returns of 55 percent. Mr. Barksdale was responsible for building Masters Capital Research and oversaw 30 consultants in multiple industry sectors, including technology, healthcare and telecom. Prior to Masters, he was a Senior Institution Equity Salesperson at Donaldson, Lufkin & Jenrette, National Westminster Bank and Kidder Peabody & Co., covering premier global asset managers. Mr. Barksdale graduated with a BA in English and History from Hampden-Sydney College in 1993. He lives in New Jersey with his wife and three children.
Edward Neugeboren Managing Director & Co-Founder (212) 972-0900 x203 office (212) 584-4548 direct edward@ledgemontcapital.com Mr. Neugeboren has experience in portfolio management, corporate management and institutional equity research. Prior to co-founding Ledgemont Capital Group, he was a Managing Director of Indigo Merchant Capital Group, involved in capital raising, management recruiting, and providing overall strategic and financial advisory services to growth stage companies. Prior to Indigo, Mr. Neugeboren was a Managing Partner of Third Ridge Capital Management, LLC, a long/short U.S. equity hedge fund, from 2001 to 2004. Third Ridge merged with Indigo in 2004. He was Chief Administrative Officer at Sorceron, an emerging Silicon Alley based media software company, from 2000 to 2001, responsible for managing corporate operations. He managed capital raising, business development and strategic planning and tactical operations. Mr. Neugeboren was Chief Administrative Officer and Director of Equity Research Operations at Lehman Brothers from 1998-2000. He was a senior member of the management team responsible for operations for a 200 person department with direct management of technology, finance, editorial and production, human resources, and compliance. Additionally, he managed the equity research business of Lehman’s strategic alliance with Fidelity Investments. He also managed the hard dollar broker-dealer research business with P&L responsibility and was the investment banking department coordinator. He was Deputy Director of Equity Research at UBS Warburg, formerly Warburg Dillon Read from 1996-1998 and Director of Equity Research Operations from 1995-1996 responsible for operations for a 150 person department. Additionally, he participated on the Investment Policy & Equity Commitment Committees. Mr. Neugeboren began his career in 1992 as an equity research analyst covering the Specialty Pharmaceuticals industry, including Generic Drugs and Drug Delivery at Dillon, Read & Co., Kidder, Peabody & Co., and Furman, Selz Inc. He was a member of top ranked Greenwich Associates Mid-Cap Pharmaceuticals Team. He serves as a member of the Board of Directors of KineMed, Inc., a private platform-based drug development company in Emeryville, California and is a past Board member of Elite Pharmaceuticals, a public specialty pharmaceutical company principally engaged in the development and manufacturing of oral controlled-release drugs. Mr. Neugeboren graduated with a BS in Economics from Union College in 1992. He lives in Connecticut with his wife and four daughters.
Jerry Treppel Managing Director (212) 972-0900 x211 office jerry@ledgemontcapital.com Mr. Treppel has over 25 years experience in healthcare equity research, investment banking, and portfolio management. He was General Partner of Wheaten HealthCare Partners LP and Principal of Wheaten Capital Management LLC, a long/short equity healthcare fund. Mr. Treppel founded Wheaten with a strategy of exploiting market inefficiencies in small- and mid-cap companies, which are largely underfollowed by Wall Street. The fund focused on diverse subsectors of healthcare, including pharmaceuticals, generic drugs, drug delivery, biotechnology, medical technology, life science tools, pharmaceutical services, managed care and healthcare facilities. Prior to Wheaten, he was a Managing Director, Equity Securities, at Banc America Securities where he covered approximately 25 companies in the Specialty Pharmaceuticals industry. Prior to that, Mr. Treppel was Head of Pharmaceutical Research at UBS Warburg. Previously, Mr. Treppel was employed in senior positions in equity research at Dillon Read, Kidder Peabody, Furman Selz, Swergold, Chefitz & Sinsabaugh, Merrill Lynch and Sloate Weisman & Murray. For the past 25 years, Mr. Treppel analyzed the area of Specialty Pharmaceuticals and created the first investor conference in the sector. Mr. Treppel has been widely recognized for his expertise in these industries, accruing accolades from Reuters, Institutional Investor, and the Wall Street Journal for excellence in industry, company knowledge, and stock picking. Mr. Treppel was among the first analysts to recommend Teva Pharmaceutical Industries Ltd. Additionally he has extensive experience in capital raising and advisory services. He also researched the health services industry being among the first to recognize the potential of the HMO industry. Prior to entering the investment industry, Mr. Treppel was employed in the health care services industry as a hospital administrator and health planner at Montefiore Medical Center and as a bench scientist researching Epstein-Barr virus. Mr. Treppel is currently on the Board of Directors of Akorn, Inc., a public specialty pharmaceutical company focused on ophthalmics, generic injectable products, contract manufacturing and vaccines, and Elite Laboratories, a public specialty pharmaceutical company specializing in oral controlled-release products. He is a past Board member of Cangene Corporation, the largest public Canadian biopharmaceutical company. He has served on the audit, compensation, and nominating committees for Akorn and Cangene. Mr. Treppel received a B.A. in Biological Sciences from Rutgers College, a Masters in Hospital Administration (MHA) from Washington University, and an MBA in Finance from NYU. He has been a CFA charter holder since 1988. Mr. Treppel lives in New Jersey with his wife and three sons.
Daniel Seto Vice President (212) 972-0900 x209 office daniel@ledgemontcapital.com Mr. Seto has experience in portfolio management and equity research. He was a Portfolio Manager/Analyst for Wheaten Capital Management LLC, a long/short equity healthcare hedge fund. As Portfolio Manager/Analyst, he identified investment opportunities and executed the fund’s strategy of exploiting market inefficiencies in small- and mid-cap companies, which are largely underfollowed by Wall Street. The fund focused on diverse subsectors of healthcare, including pharmaceuticals, generic drugs, drug delivery, biotechnology, medical technology, life science tools, pharmaceutical services, managed care and healthcare facilities. Prior to Wheaten Capital, he was an Associate Analyst at Banc of America Securities covering the Specialty Pharmaceuticals industry, which included generic drug, drug delivery, specialty marketing, and drug development companies, from 1999 to 2003. At Banc of America, Mr. Seto’s responsibilities included authoring research reports, constructing detailed financial models, presenting investment ideas to institutional clients and developing relationships with senior management within the sector. He also served as Research Associate covering Specialty Pharmaceuticals at UBS Warburg, formerly Warburg Dillon Read, from 1996 to 1999. Mr. Seto began his investment career as a special situations Analyst at Value Line. Mr. Seto graduated with BA in Economics from the University of Michigan in 1993. He has been a CFA charter holder since 2005. Mr. Seto lives in New York City.
Kerry Kittles Associate (212) 972-0900 kerry@ledgemontcapital.com After graduating with a degree in Business Management from Villanova University, Mr. Kittles was selected by the New Jersey Nets as the eight pick in the 1996 NBA Draft. After eight seasons with the Nets, Mr. Kittles was traded to the Los Angeles Clippers, where he played between 2004 and 2005. He received an MBA at Villanova University’s School of Business. He lives in New Jersey, with his wife and three daughters. Damon Cameron Associate (212) 584-4547 direct damon@ledgemontcapital.com Mr. Cameron began his career as an Associate at Ledgemont in July of 2010. Prior to joining our firm full-time, he held Summer Analyst positions through 2008 and 2009 with Ledgemont. Mr. Cameron graduated with a BA in Economics and Commerce from Hampden-Sydney College in 2010.